New combo therapy aims to wipe out colon cancer before surgery
NCT ID NCT06368141
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase 2 trial tests whether adding an immunotherapy drug (serplulimab) to standard chemotherapy before surgery can improve outcomes for people with locally advanced colon cancer. About 56 participants will receive the combination, then undergo surgery. The main goal is to see if the cancer completely disappears after treatment, and whether this leads to better long-term survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Serplulimab (an immunotherapy drug) combined with capecitabine and oxaliplatin (chemotherapy)
- What this could lead to
- If successful, this combination could become a new standard treatment before surgery for locally advanced colon cancer, potentially increasing the chance of eliminating all cancer cells and improving long-term survival.
- What could go wrong
- This is a small, early-phase trial with only 56 participants, so results may not apply to all patients. Immunotherapy can cause immune-related side effects, and the added benefit over chemotherapy alone is not yet proven.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLON CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ruijin Hospital
RECRUITINGShanghai, Shanghai Municipality, 200025, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can we predict who will survive a bowel surgery leak?
- Can a new drug ST316 shrink Hard-to-Treat tumors?
- Dye-Free laser imaging could replace standard dye in colorectal surgery
- Polyp recurrence after colon cancer surgery: a clue to better Follow-Up?
- Experimental pill SHY-ONC6 takes on Hard-to-Treat cancers
- Simple blood draws could predict colon cancer treatment success